Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 6Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Neoplasms 1Lymphoma, Mantle-Cell 1

Interventions

Rituximab 6Lenalidomide 3Bendamustine Hydrochloride 3pirtobrutinib 2Cyclophosphamide 2venetoclax 1umbralisib 1ublituximab 1tocilizumab 1obinutuzumab 1idelalisib 1glofitamab 1fludarabine 1atezolizumab 1acalabrutinib 1Vincristine 1Standard of Care 1Prednisone 1Doxorubicin 1Brentuximab Vedotin 1Appointments and Schedules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Lymphoma, Non-Hodgkin × Lenalidomide × Clear all
NCT05409066 2025-07-28

EPCORE FL-1

Genmab

Phase 3 Active not recruiting
549 enrolled 2 FDA
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01996865 2025-07-10

MAGNIFY

Celgene

Phase 3 Completed
503 enrolled 18 charts 1 FDA
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01938001 2023-02-22

AUGMENT

Celgene

Phase 3 Completed
358 enrolled 18 charts 1 FDA
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡